Efficacy of intradermal injection of tranexamic acid and ascorbic acid versus tranexamic acid and placebo in the treatment of melasma: A split-face comparative trial.
MASI score
ascorbic acid
melasma
split‐face injection
tranexamic acid
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
18
06
2021
revised:
23
11
2021
accepted:
07
12
2021
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Melasma is a common dermatologic disorder characterized by symmetrical hyperpigmented lesions on the face. Although various therapeutic options are available for melasma, its treatment remains challenging. The present study evaluated the safety and efficacy of intradermal microinjection of tranexamic acid (TA) plus ascorbic acid in treating melasma lesions compared with TA and placebo. From September 2019 to May 2020, 24 patients with symmetrical melasma were enrolled in a prospective, double-blind, split-face, randomized controlled clinical trial. Each patient received 50 mg/ml TA and 50 mg/ml ascorbic acid for one side of the face (A) and 50 mg/ml TA and placebo for the other side (B) every 2 weeks for 12 weeks. The Melasma Area and Severity Index (MASI) score, Physician Global Assessment, and pain were measured at baseline and at 4, 8, 12, and 24 weeks. Statistical analysis was done using SPSS software version 16, and data were reported as mean ± standard deviation or median and interquartile range. Both groups experienced a significant decrease in MASI scores compared with the baseline. The MASI score was significantly less in the intervention group than the placebo group at the 8th and 12th weeks. However, burning pain was significantly more prominent in the intervention group. Intradermal injection of ascorbic acid combined with TA can be beneficial in treating melasma. Currently, there are numerous treatment modalities for melasma. However, the results still vary, and satisfactory outcomes are yet to be reached.
Sections du résumé
Background and Aims
UNASSIGNED
Melasma is a common dermatologic disorder characterized by symmetrical hyperpigmented lesions on the face. Although various therapeutic options are available for melasma, its treatment remains challenging. The present study evaluated the safety and efficacy of intradermal microinjection of tranexamic acid (TA) plus ascorbic acid in treating melasma lesions compared with TA and placebo.
Methods
UNASSIGNED
From September 2019 to May 2020, 24 patients with symmetrical melasma were enrolled in a prospective, double-blind, split-face, randomized controlled clinical trial. Each patient received 50 mg/ml TA and 50 mg/ml ascorbic acid for one side of the face (A) and 50 mg/ml TA and placebo for the other side (B) every 2 weeks for 12 weeks. The Melasma Area and Severity Index (MASI) score, Physician Global Assessment, and pain were measured at baseline and at 4, 8, 12, and 24 weeks. Statistical analysis was done using SPSS software version 16, and data were reported as mean ± standard deviation or median and interquartile range.
Results
UNASSIGNED
Both groups experienced a significant decrease in MASI scores compared with the baseline. The MASI score was significantly less in the intervention group than the placebo group at the 8th and 12th weeks. However, burning pain was significantly more prominent in the intervention group.
Conclusion
UNASSIGNED
Intradermal injection of ascorbic acid combined with TA can be beneficial in treating melasma. Currently, there are numerous treatment modalities for melasma. However, the results still vary, and satisfactory outcomes are yet to be reached.
Identifiants
pubmed: 35284654
doi: 10.1002/hsr2.537
pii: HSR2537
pmc: PMC8905661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e537Informations de copyright
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Br J Dermatol. 2003 Sep;149(3):572-7
pubmed: 14510991
Am J Clin Dermatol. 2020 Apr;21(2):173-225
pubmed: 31802394
J Dermatolog Treat. 2018 Jun;29(4):405-410
pubmed: 29027510
Dermatol Ther. 2017 May;30(3):
pubmed: 28133910
Health Sci Rep. 2022 Mar 09;5(2):e537
pubmed: 35284654
J Cosmet Laser Ther. 2008 Dec;10(4):234-6
pubmed: 18830869
Eur J Haematol. 2020 Feb;104(2):79-87
pubmed: 31729076
Australas J Dermatol. 2017 Aug;58(3):e105-e108
pubmed: 27173008
J Cosmet Dermatol. 2019 Dec;18(6):1700-1704
pubmed: 30920111
J Cosmet Laser Ther. 2017 Oct;19(5):294-299
pubmed: 28388246
J Cutan Aesthet Surg. 2013 Jul;6(3):139-43
pubmed: 24163529
J Clin Diagn Res. 2017 Sep;11(9):WC08-WC11
pubmed: 29207818
Pigment Cell Melanoma Res. 2018 Jul;31(4):461-465
pubmed: 29285880
J Cosmet Dermatol. 2019 Oct;18(5):1342-1347
pubmed: 30770637
Int J Dermatol. 2004 Aug;43(8):604-7
pubmed: 15304189
J Cosmet Dermatol. 2019 Oct;18(5):1416-1421
pubmed: 30735611
Nursing. 2006 Jun;36(6):20
pubmed: 16741399
J Dermatolog Treat. 2007;18(1):5-9
pubmed: 17365259
Dermatol Ther (Heidelb). 2017 Sep;7(3):305-318
pubmed: 28726212